Depomed Receives FDA Approval of Proquin XR for Uncomplicated Urinary Tract Infections.MENLO PARK, Calif. -- Depomed, Inc. (Nasdaq:DEPO DEPO Delegated Episcopal Pastoral Oversight DEPO Devils Postpile National Monument (US National Park Service) DEPO Defence Export Promotion Organization (Pakistan) DEPO Double Even Pass Odd ) announced today that it has received approval from the United States Food and Drug Administration United States Food and Drug Administration (FDA), n.pr a unit of the Public Health Service created to protect the health of the nation against impure and unsafe foods, drugs, and cosmetics. (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) for Proquin(TM) XR, a once-daily, extended-release formulation of ciprofloxacin hydrochloride ciprofloxacin hydrochloride Ciloxam, Cipro, Cipro I.V., Cipro XR, Ciproxin (UK) Pharmacologic class: Fluoroquinolone Therapeutic class: Anti-infective Pregnancy risk category C for the treatment of uncomplicated urinary tract infections (UTIs). Proquin XR is the first version of ciprofloxacin ciprofloxacin /cip·ro·flox·a·cin/ (sip?ro-flok´sah-sin) a synthetic antibacterial effective against many gram-positive and gram-negative bacteria; used as the hydrochloride salt.cip·ro·flox·a·cin n. with nausea and diarrhea listed as "uncommon" adverse events in its label, rather than "common" adverse events. As a class of compounds, ciprofloxacin and other fluoroquinolones are cited in literature as causing nausea and diarrhea and these types of side effects Side effects Effects of a proposed project on other parts of the firm. are reportedly the most frequent reason that patients discontinue ciprofloxacin treatment. "Urinary tract infections result in an estimated 10 million doctor visits each year, and the most frequently prescribed drug is ciprofloxacin," said Neal Shore, M.D., medical director, Carolina Urologic Research Center. "Proquin XR is a new, once-daily version of ciprofloxacin that caused fewer incidences of gastrointestinal side effects, including nausea and diarrhea, in the recent multicenter Phase III clinical trial Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the of over 1,000 patients." According to Depomed's own dissolution studies, CIPRO Cip·ro A trademark for ciprofloxacin and its hydrochloride derivative. ciprofloxacin hydrochloride Ciloxam, Cipro, Cipro I.V. (R) and generic equivalents release their entire dosage within approximately 30 minutes and even once-daily CIPRO XR releases its dosage within approximately two hours, while Proquin XR is designed to gradually release the drug over six hours. This extended release avoids large quantities of drug being dumped into the patient's intestinal system, where it can cause side effects or interactions with gastrointestinal drugs. In a randomized ran·dom·ize tr.v. ran·dom·ized, ran·dom·iz·ing, ran·dom·iz·es To make random in arrangement, especially in order to control the variables in an experiment. , double-blind, Phase III clinical trial of 1,037 patients with uncomplicated UTIs, Proquin XR eradicated the bacteria most commonly responsible for causing UTIs comparably to twice-daily CIPRO. "Proquin XR is Depomed's first FDA approved product, and it is a testament not only to the benefits of our Gastric Retention (GR) extended-release drug delivery system, but to our scientific and regulatory teams," said John W. Fara, Ph.D., chairman, president and chief executive officer of Depomed. "This approval precedes next month's anticipated FDA decision regarding the New Drug Application seeking approval for Glumetza(TM) for the treatment of Type II diabetes Type II diabetes Type II diabetes is the most common form of diabetes and usually appears in middle aged adults. It is often associated with obesity and may be delayed or controlled with diet and exercise. Mentioned in: Diabetic Ketoacidosis . We are now well on our way to generating our first product revenue and realizing our goal of providing improved medicines to patients." Depomed's New Drug Application for Proquin XR was submitted in July 2004, just four years after Depomed initiated development of this novel formulation of ciprofloxacin. The market for ciprofloxacin is estimated at $1.5 billion worldwide in the U.S., with prescriptions for uncomplicated UTI's representing a significant portion of usage. Depomed is currently in the final stages of negotiations with potential marketing partners for Proquin XR. About Proquin(TM) XR Proquin XR is a once-daily extended-release formulation of ciprofloxacin hydrochloride and is intended to treat uncomplicated urinary tract infections (UTIs). UTIs are bacterial infections frequently caused by E. coli E. coli: see Escherichia coli. E. coli in full Escherichia coli Species of bacterium that inhabits the stomach and intestines. E. coli can be transmitted by water, milk, food, or flies and other insects. and are typically treated with antibiotics. Patients should not take Proquin XR if they are allergic to, or have ever had a severe reaction to, ciprofloxacin or to any other "quinolone" antibiotics. Proquin XR is generally well tolerated. The most common side effects with Proquin XR include vaginal yeast infection Vaginal yeast infection An overgrowth of fungus in the vaginal area. Mentioned in: Jock Itch and headache. For additional information on Proquin XR, please call the product information hotline at 800-206-2945. Gastric Retention Technology Depomed's Gastric Retention (GR)(TM) system is a patented, oral drug delivery technology designed specifically for drugs that are preferentially absorbed high in the gastrointestinal tract. Using normal physiological processes by which the stomach retains large objects for further digestion, the GR System swells following ingestion ingestion /in·ges·tion/ (-chun) the taking of food, drugs, etc., into the body by mouth. in·ges·tion n. 1. The act of taking food and drink into the body by the mouth. 2. and is retained in the stomach for a number of hours, while it continuously releases the incorporated drug at a controlled rate to absorption sites in the upper intestinal tract. The controlled release of the drug at the preferred absorption site is intended to optimize delivery of the drug during the "therapeutic window," potentially increasing its therapeutic benefits and potentially decreasing gastrointestinal side effects. GR-based products are designed to provide once daily administration, and potentially improve patient convenience, compliance and pharmacokinetic profiles. About Depomed Depomed, Inc. is a specialty pharmaceutical company utilizing its innovative Gastric Retention (GR) system to develop novel oral products and improved, extended release formulations of existing oral drugs. GR-based products are designed to provide once daily administration and reduced gastrointestinal side effects, improving patient convenience, compliance and pharmacokinetic profiles. Once daily Proquin(TM) XR (ciprofloxacin hydrochloride) extended-release tablets for the treatment of uncomplicated urinary tract infections has been approved by the FDA, and regulatory applications for once daily Glumetza(TM) (metformin metformin /met·for·min/ (met-for´min) an antihyperglycemic agent that potentiates the action of insulin, used in the treatment of type 2 diabetes mellitus. met·for·min n. GR) for the treatment of Type II diabetes are pending in the U.S. and Canada. The company is also conducting a Phase II trial in post herpetic neuralgia neuralgia (n  răl`jə, ny–), acute paroxysmal pain along a peripheral sensory nerve. with the drug Gabapentin GR. Additional information about Depomed may be found at its web site, www.depomedinc.com. "Safe Harbor" Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to those related to our research and development efforts, including preclinical and clinical testing; regulation by the FDA and other government agencies; the timing of regulatory applications and product launches; and other risks detailed in the Company's Securities and Exchange Commission filings, including the Company's Annual Report on Form 10-K. You are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date hereof. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion